A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Erlotinib in Subjects With Lung Adenocarcinoma With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Phase of Trial: Phase I
Latest Information Update: 17 Aug 2016
At a glance
- Drugs SNX 5422 (Primary) ; Erlotinib
- Indications Lung cancer
- Focus Adverse reactions
- Sponsors Esanex
- 15 Aug 2016 Status changed from active, no longer recruiting to completed.
- 23 May 2016 Planned End Date changed from 1 May 2016 to 1 Aug 2016.
- 19 Nov 2015 Planned End Date changed from 1 Feb 2016 to 1 May 2016 as reported by ClinicalTrials.gov record.